ChiCTR2100052292 版本V1.1 版本创建时间2022/04/25 21:13:02 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052292 

最近更新日期:

Date of Last Refreshed on:

2021-10-24 01:44:17 

注册时间:

Date of Registration:

2021-10-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

藏药“十一味维命胶囊”治疗失眠症临床疗效评价研究

Public title:

Evaluation of the clinical effect of Shiyiweiming capsule on insomnia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

藏药“十一味维命胶囊”治疗失眠症临床疗效评价研究

Scientific title:

Evaluation of the clinical effect of Shiyiweiming capsule on insomnia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

昝占全 

研究负责人:

仁青东主 

Applicant:

ZanZhanquan 

Study leader:

Renqingdongzhu 

申请注册联系人电话:

Applicant telephone:

13139054904

研究负责人电话:

Study leader's
telephone:

15297189073

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

583169281@qq.com

研究负责人电子邮件:

Study leader's E-mail:

rqdz@yahoo.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

青海省西宁市生物科技产业园区经三路18号

研究负责人通讯地址:

青海省西宁市城北区宁大路251号

Applicant address:

18 Jingsan road, Qinghai Biotechnology Industrial Park, Xining, Qinghai Province

Study leader's address:

No. 251, Ningda Road, Chengbei district, Xining, Qinghai Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

青海久美藏医院有限公司

Applicant's institution:

Qinghai Jiumei Tibetan Hospital Co. , Ltd.

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

jmzy2020—R002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青海久美藏医院有限公司医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Qinghai Jiumei Tibetan Hospital Co. , Ltd.

伦理委员会批准日期:

Date of approved by ethic committee:

2020-07-29 00:00:00

伦理委员会联系人:

久美彭措

Contact Name of the ethic committee:

jiumeipengcuo

伦理委员会联系地址:

青海省西宁市生物科技产业园区经三路18号

Contact Address of the ethic committee:

18 Jingsan road, Qinghai Biotechnology Industrial Park, Xining, Qinghai Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

15001106999

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青海久美藏医院有限公司

Primary sponsor:

Qinghai Jiumei Tibetan Hospital Co. , Ltd.

研究实施负责(组长)单位地址:

青海省西宁市生物科技产业园区经三路18号

Primary sponsor's address:

18 Jingsan road, Qinghai Biotechnology Industrial Park, Xining, Qinghai Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

青海

市(区县):

西宁

Country:

China

Province:

Qinghai

City:

Xi'ning

单位(医院):

青海久美藏医院有限公司

具体地址:

生物科技产业园区经三路18号

Institution
hospital:

Qinghai Jiumei Tibetan Hospital Co. , Ltd.

Address:

18 Jingsan Road, Biotechnology Industrial Park

经费或物资来源:

企业自筹、政府扶持(后补助)

Source(s) of funding:

Enterprise self-financing, government support (after subsidies)

研究疾病:

失眠症  

Target disease:

Insomnia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机抽样 

Study design:

Randomly Sampling 

研究目的:

临床疗效再评价  

Objectives of Study:

Reevaluation of clinical efficacy

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合符合ICD-10 失眠症诊断标准;
(2)性别不限,年龄在18—65(包含18岁和65岁)周岁之间;
(3)受试者均为自愿参加临床试验研究,并签署了知情同意书者 ;

Inclusion criteria

(1) meet the ICD-10 diagnostic criteria for insomnia;
(2) be of any sex and be between the ages of 18 and 65;
(3) be willing to participate in clinical trial and sign informed consent;

排除标准:

(1)任何干扰试验进程或可能干扰睡眠的生活方式:如最近两周内或试验阶段,会有跨越时区的旅行或倒班(夜班白班倒替)等;
(2)试验期间内需操作机械的特殊职业者,如职业司机,高空作业者等;
(3)每天规律饮用过量茶、咖啡饮料者。
(4)排除因其他疾病引发的失眠如:发作性睡病、呼吸相关性睡眠障等;
(5)过去一年内有肿瘤、心肌梗塞、心力衰竭者、 精神异常病史、 药物滥用史、 药物成瘾史;
(6)伴有心、肝、肾及呼吸功能受损者或其他各系统严重疾病, AST或ALT超过正常值上限的1.5倍,血清肌酐超过正常值上限;
(7)筛选时HAMA焦虑量表评分大于14 分, HAMD抑郁量表≥17分;
(8)排除特殊人群:过敏体质、备孕、妊娠或哺乳期妇女、对本药物成分过敏者;
(9)3个月内参加其他临床研究的患者;
(10)呼吸暂停类患者;
(11)入组后服用影响醒睡功能或影响试验药物评价的患者;

Exclusion criteria:

(1) any lifestyle that interferes with the trial process or may interfere with sleep: If within the last two weeks or during the trial period, there will be travel or shifts across time zones (night shifts, day shifts) , etc. ; (2) special workers who need to operate machinery during the trial period, such as professional drivers, high-altitude workers and so on; (3) daily regular consumption of excessive tea, coffee drinks. (4) exclusion of insomnia caused by other diseases such as Narcolepsy, respiratory-related sleep disorders; (5) history of cancer, myocardial infarction, heart failure, history of mental disorders, history of Drug Abuse, history of drug addiction in the past year; (6) patients with heart, liver, kidney and respiratory function impairment or other serious diseases, AST or ALT were 1.5 times higher than the upper limit of normal value, serum creatinine was higher than the upper limit of normal value; (7) Hama anxiety scale score was higher than 14 when screening; Hamd Depression scale ≥17 points (8) excluded special population: Allergic Constitution, pregnancy, pregnancy or lactation women, allergic to the drug ingredients; (9) patients who participated in other clinical studies within 3 months; (10) patients with apnea; (11) the patients who took the drug after entering the group could affect the function of waking and sleeping or the evaluation of the drug in the test

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-01 00:00:00 To 2023-11-30 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

100

Group:

Experimental group

Sample size:

干预措施:

十一味维命胶囊

干预措施代码:

Intervention:

Shiyiwei Weiming Capsule

Intervention code:

组别:

对照组

样本量:

100

Group:

Control group

Sample size:

干预措施:

安慰剂

干预措施代码:

Intervention:

Placebo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

青海 

市(区县):

西宁 

Country:

China

Province:

Qinghai

City:

Xi'ning

单位(医院):

青海久美藏医院有限公司 

单位级别:

 

Institution
hospital:

Qinghai Jiumei Tibetan Medicine Co. , Ltd.

Level of the institution:

测量指标:

Outcomes:

指标中文名:

脑涨落图

指标类型:

主要指标

Outcome:

Brain fluctuation map

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

多导睡眠监测

指标类型:

主要指标

Outcome:

Polysomnography

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠量表

指标类型:

主要指标

Outcome:

Pittsburgh sleep scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

大体评定量表

指标类型:

主要指标

Outcome:

General rating scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁量表

指标类型:

主要指标

Outcome:

Depression scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

HAMA焦虑量表

指标类型:

主要指标

Outcome:

HAMA anxiety scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

大便

组织:

Sample Name:

Faeces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化双盲试验设计

Randomization Procedure (please state who generates the random number sequence and by what method):

Design of randomized double-blind trial

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No sharing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record sheet

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-24 01:44:07